59 related articles for article (PubMed ID: 19191288)
1. HPV detection rate in discordant Pap tests between cytotechnologists and pathologists.
Chhieng DC; Bakdounes K; Connolly M; Gallaspy S; Roberson J; Eltoum I
Diagn Cytopathol; 2009 May; 37(5):320-3. PubMed ID: 19191288
[TBL] [Abstract][Full Text] [Related]
2. High-risk HPV DNA detection rate in patients with atypical squamous cells and its relationship to the atypical squamous cell: squamous intraepithelial lesion ratio.
Chhieng DC; Chen J; Connolly K; Roberson J; Eltoum I
Acta Cytol; 2006; 50(3):291-4. PubMed ID: 16780023
[TBL] [Abstract][Full Text] [Related]
3. Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases.
Knoepp SM; Kuebler DL; Wilbur DC
Diagn Mol Pathol; 2007 Sep; 16(3):125-9. PubMed ID: 17721319
[TBL] [Abstract][Full Text] [Related]
4. HPV DNA testing of the residual sample of liquid-based Pap test: utility as a quality assurance monitor.
Zuna RE; Moore W; Dunn ST
Mod Pathol; 2001 Mar; 14(3):147-51. PubMed ID: 11266518
[TBL] [Abstract][Full Text] [Related]
5. The prevalence of HR-HPV DNA in ASC-US Pap smears: A military population study.
Stany MP; Bidus MA; Reed EJ; Kaplan KJ; McHale MT; Rose GS; Elkas JC
Gynecol Oncol; 2006 Apr; 101(1):82-5. PubMed ID: 16290002
[TBL] [Abstract][Full Text] [Related]
6. ASC/SIL Ratio for Cytotechnologists: A surrogate marker of screening sensitivity.
Renshaw AA; Deschênes M; Auger M
Am J Clin Pathol; 2009 Jun; 131(6):776-81. PubMed ID: 19461082
[TBL] [Abstract][Full Text] [Related]
7. ASC/SIL ratio for cytotechnologists: A survey of its utility in clinical practice.
Renshaw AA; Auger M; Birdsong G; Cibas ES; Henry M; Hughes JH; Moriarty A; Tench W; Wilbur DC; Elsheikh TM
Diagn Cytopathol; 2010 Mar; 38(3):180-3. PubMed ID: 19760762
[TBL] [Abstract][Full Text] [Related]
8. Human papillomavirus DNA detection in ThinPrep Pap test vials is independent of cytologic sampling of the transformation zone.
Zhao C; Austin RM
Gynecol Oncol; 2007 Nov; 107(2):231-5. PubMed ID: 17854873
[TBL] [Abstract][Full Text] [Related]
9. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test: a 5-year follow-up study of Papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria.
Thrall MJ; Pambuccian SE; Stelow EB; McKeon DM; Miller L; Savik K; Gulbahce HE
Cancer; 2008 Jun; 114(3):171-9. PubMed ID: 18454461
[TBL] [Abstract][Full Text] [Related]
10. Age-specific detection of high risk HPV DNA in cytologically normal, computer-imaged ThinPrep Pap samples.
Cibas ES; Hong X; Crum CP; Feldman S
Gynecol Oncol; 2007 Mar; 104(3):702-6. PubMed ID: 17150245
[TBL] [Abstract][Full Text] [Related]
11. Impact of reflex HPV testing on interpretation and management of ThinPrep Pap tests.
Peng Y; Wang HH
Diagn Cytopathol; 2006 Aug; 34(8):585-8. PubMed ID: 16850488
[TBL] [Abstract][Full Text] [Related]
12. Cytologic-histologic correlation of screening and diagnostic Papanicolaou tests.
Chute DJ; Covell J; Pambuccian SE; Stelow EB
Diagn Cytopathol; 2006 Jul; 34(7):503-6. PubMed ID: 16783779
[TBL] [Abstract][Full Text] [Related]
13. Cervical specimens collected in liquid buffer are suitable for both cytologic screening and ancillary human papillomavirus testing.
Sherman ME; Schiffman MH; Lorincz AT; Herrero R; Hutchinson ML; Bratti C; Zahniser D; Morales J; Hildesheim A; Helgesen K; Kelly D; Alfaro M; Mena F; Balmaceda I; Mango L; Greenberg M
Cancer; 1997 Apr; 81(2):89-97. PubMed ID: 9126136
[TBL] [Abstract][Full Text] [Related]
14. The utility of human papillomavirus testing in the management of atypical glandular cells on cytology.
Sharpless KE; O'Sullivan DM; Schnatz PF
J Low Genit Tract Dis; 2009 Apr; 13(2):72-8. PubMed ID: 19387126
[TBL] [Abstract][Full Text] [Related]
15. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
Zhao C; Austin RM
Cancer; 2008 Aug; 114(4):242-8. PubMed ID: 18484643
[TBL] [Abstract][Full Text] [Related]
17. ASC-US and high-risk HPV testing: performance in daily clinical practice.
Selvaggi SM
Diagn Cytopathol; 2006 Nov; 34(11):731-3. PubMed ID: 17041955
[TBL] [Abstract][Full Text] [Related]
18. [Diagnostic concordance in gynecologic cytology].
Lazcano Ponce EC; de Ruiz PA; Martínez Arias C; Murguía Riechers L
Rev Invest Clin; 1997; 49(2):111-6. PubMed ID: 9380963
[TBL] [Abstract][Full Text] [Related]
19. Verrucous carcinoma of the cervix: detection of carcinogenetic human papillomavirus types and their role during follow-up.
Frega A; Lukic A; Nobili F; Palazzo A; Iacovelli R; French D; Moscarini M
Anticancer Res; 2007; 27(6C):4491-4. PubMed ID: 18214065
[TBL] [Abstract][Full Text] [Related]
20. High-risk HPV DNA detected in less than 2% of over 25,000 cytology negative imaged liquid-based Pap test samples from women 30 and older.
Bansal M; Austin RM; Zhao C
Gynecol Oncol; 2009 Nov; 115(2):257-61. PubMed ID: 19665217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
